Holen Sie sich die Stockscreener-App
4.64
1.54%
-0.08
Schlusskurs vom Vortag:
$4.72
Offen:
$4.75
24-Stunden-Volumen:
1.65M
Relative Volume:
0.38
Marktkapitalisierung:
$1.62B
Einnahmen:
$143.05M
Nettoeinkommen (Verlust:
$-145.99M
KGV:
-10.84
EPS:
-0.4282
Netto-Cashflow:
$-134.06M
1W Leistung:
+9.60%
1M Leistung:
-4.97%
6M Leistung:
-41.98%
1J Leistung:
+102.05%
1-Tages-Spanne:
$4.63
$4.7999
1-Wochen-Bereich:
$4.235
$4.89
52-Wochen-Spanne:
$1.57
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
332-208-6102
Adresse
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.645 | 1.64B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
437.04 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.65 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.98 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.13 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.96 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-19 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-30 | Eingeleitet | Jefferies | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
NUVB: IBTROZI's rapid first-line growth and robust pipeline drive strong outlook and financial stability - TradingView
NUVB: IBTROZI's strong first-line growth and pipeline progress drive optimism for future expansion - TradingView
Truist Securities Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation - MSN
Nuvation Bio (NUVB) Collaborates with Thermo Fisher - Insider Monkey
Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug - MSN
NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill
NUVB: All proposals passed, including director elections and auditor ratification, with strong quorum - TradingView
Nuvation bid to expand Ibtrozi label undergoes FDA review - MSN
NUVB: IBTROZI and safusidenib drive growth, with new DDC platform updates and strong financial runway - TradingView
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps - Yahoo Finance
Are options traders betting on a big move in Nuvation Bio stock? - MSN
Earnings call transcript: Nuvation Bio Q1 2026 revenue beats forecast, stock jumps - Investing.com Nigeria
David Abrams's Nuvation Bio Inc(NUVB) Holding History - GuruFocus
Nuvation Bio Inc. (NUVB) reports next week: Wall Street expects earnings growth - MSN
Nuvation Bio Completes IBTROZI Manufacturing Tech Transfer to Thermo Fisher - Contract Pharma
Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment - Moomoo
Nuvation Bio stock (US55043Q1004): Manufacturing deal with Thermo Fisher for lung cancer drug - AD HOC NEWS
Nuvation Bio To Collaborate With Thermo Fisher Scientific For U.S.-Based Manufacturing Of Ibtrozi For Ros1-Positive Non-Small Cell Lung Cancer - TradingView
Nuvation Bio partners with Thermo Fisher for US drug manufacturing By Investing.com - Investing.com South Africa
Nuvation Bio partners with Thermo Fisher for US drug manufacturing - Investing.com
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire
NUVB: ZUSDURI’s rapid growth and durable results drive expansion, with a robust pipeline fueling future opportunities - TradingView
Is Nuvation Bio (NUVB) the Best Penny Stock to Buy Before It Explodes? - Insider Monkey
10 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement f - The National Law Review
Hot Picks: Biotech stocks gain on cancer drugs and trial data - BNN Bloomberg
A Look At Nuvation Bio (NUVB) Valuation After Profit Shift And Taletrectinib FDA And Guideline Milestones - Sahm
Nuvation Bio Signals Durable Momentum in Earnings Call - TipRanks
Why Nuvation Bio (NUVB) Is Up 8.1% After FDA Accepts IBTROZI Label Update, Strong Q1 Results - Sahm
Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
Nuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Finance
Nuvation Bio Inc. (NUVB) Investor Outlook: Exploring the 156% Potential Upside in Cancer Drug Innovation - DirectorsTalk Interviews
Law firm investigates Nuvation Bio's directors for possible breach of fiduciary duties. - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB) - PR Newswire
Nuvation Bio’s cancer drug sNDA accepted by FDA for review - Investing.com UK
Nuvation Bio’s cancer drug sNDA accepted by FDA for review By Investing.com - Investing.com South Africa
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer - Investing News Network
Nuvation Bio Inc. (NUVB) lags Q1 earnings estimates - MSN
Lung cancer drug with 4-year response data gets FDA review - Stock Titan
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire
Undervalued Penny Stocks To Watch In May 2026 - simplywall.st
MSN Money - MSN
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch progress By Investing.com - Investing.com India
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Wedbush Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nuvation Bio's CEO and CFO line up four investor webcasts in May - Stock Titan
NUVB Stock Rallies As IBTROZI Drives Surprise Profit - StocksToTrade
Nuvation Bio Inc. 2026 Q1 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
A Quick Look at Today's Ratings for Nuvation Bio(NUVB.US), With a Forecast Between $12 to $20 - Moomoo
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):